1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
624C798B3FB10312285257C760058AB48
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-pharma-social-media-listening-adverse-events-reporting-and-program-approval-process?opendocument
18
19opendocument
203.85.214.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Digital Marketing

Pharma Social Media Listening: Adverse Event Reporting and Program Approval Process

ID: 5291


Features:

18 Info Graphics

8 Data Graphics

58 Metrics

15 Narratives


Pages/Slides: 31


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Pharma Social Media Listening: Adverse Event Reporting and Program Approval Process."

STUDY BACKGROUND

In an era of burgeoning social media websites, organizations across industry sectors are turning to social media listening as an effective way to capture consumer insights. Online disease state discussion among patients, physicians, caregivers and other key customer groups is flourishing. This is causing savvy healthcare companies to launch innovative Social Media Listening programs to capture critical market insights. For the pharmaceutical sector, social media listening can fill in critical business knowledge gaps around patient adherence, brand awareness, and therapeutic area/disease state perspectives.


Best Practices, LLC conducted this study to help healthcare companies better understand current industry approaches to issues surrounding the approval of Social Media Listening (SML) projects, and the concerns and relevance of Adverse Event reporting associated with SML projects. The study delivers crucial benchmarks and qualitative insights from industry-leading companies on approval processes, and Adverse Events reporting and management. Market research, digital/social media and marketing leaders can use this research to compare and enhance their Social Media Listening programs.


KEY TOPICS

  • Gaining Social Media Listening Approval
  • Adverse Events Management & Compliance
  • Innovative Strategies & Tactics for Winning Listening Approval

SAMPLE KEY METRICS
  • Which Functions Primarily Leads the Social Media Listening (SML) Program Operations
  • Frequency of Approvals Gained by SML Teams for Listening Activities
  • Importance of Adverse Events (AE) Management in Establishing Listening Programs
  • Use of Metrics to Track AE
  • Steps Taken to Ensure AE Monitoring & Reporting Compliance
  • Number of AE Encountered
SAMPLE KEY FINDING
  • Top Listening Benefits Involve Rapid Project Insights: Primary Listening benefits include: rapid snapshots on brand awareness & loyalty, patient adherence trends, patient journey mapping, sentiment analysis, issues and objection handling (for physicians), misinformation levels, and "picking out cherries" of a qualitative nature to share back with brand leaders.

STUDY METHODOLOGY

Fifteen Digital & Social Marketing and Market Research leaders at 13 large global healthcare organizations participated in this study via deep-dive interviews. Six of the top 10 largest pharmaceutical organizations are represented in this research, and more than half of all respondents work at the director level or above.

Industries Profiled:
Biotech; Professional Services; Pharmaceutical; Health Care; Medical Device; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
CSL Behring; Straumann; Pfizer; Boston Scientific; Astellas; Johnson & Johnson; Novartis; Shire; Amgen; Sanofi; EMD Serono; GlaxoSmithKline ; Abbvie

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.